A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia
Table 1
Demographic characteristics of patients participating in olanzapine and risperidone groups.
Variables
Olanzapine ()
Risperidone ()
95% CI
Age, y
36.89 ± 3.52
38.44 ± 4.91
1.283
0.205
−0.763, 3.481
Age at onset, y
22.48 ± 3.74
23.62 ± 4.91
0.923
0.360
−1.25, 3.17
Duration of illness, y
6.83 ± 1.63
6.39 ± 1.58
0.969
0.337
−2.28, 3.24
Number of prior episodes Mean ± SD
7.18 ± 2.13
6.82 ± 1.51
0.65
0.51
−1.46, 0.74
Baseline SAPS
63.61 ± 3.86
62.19 ± 4.11
1.379
0.1731
−0.64, 3.48
Baseline SANS
46.26 ± 3.37
46.83 ± 3.75
−0.619
0.5382
−2.41, 1.27
Baseline SAI
3.49 ± 0.61
3.51 ± 1.03
−0.092
0.9274
−0.46, 0.42
Baseline SAS
0.35 ± 0.76
0.35 ± 0.76
0.000
1.0000
−0.39, 0.39
Baseline CGI-S
3.65 ± 1.16
3.25 ± 0.12
1.879
0.0653
−0.03, 0.83
SAPS: Scale for Assessment of Positive Symptoms; SANS: Scale for Assessment of Negative Symptoms; CGI-S: Clinical Global Impressions-Severity Scale; SAI: Schedule for Assessment of Insight; and SAS: Simpson Angus Scale.
